312 related articles for article (PubMed ID: 8396640)
1. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical axis level.
Alcaraz C; Vargas ML; Fuente T; Milanés MV
J Pharmacol Exp Ther; 1993 Sep; 266(3):1602-6. PubMed ID: 8396640
[TBL] [Abstract][Full Text] [Related]
2. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level.
Alcaraz C; Milanés MV; Vargas ML
J Pharmacol Exp Ther; 1993 Sep; 266(3):1385-9. PubMed ID: 8396634
[TBL] [Abstract][Full Text] [Related]
3. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
Millan MJ; Morris BJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
[TBL] [Abstract][Full Text] [Related]
4. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
Iyengar S; Kim HS; Wood PL
J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
[TBL] [Abstract][Full Text] [Related]
5. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
Milanés MV; Vargas ML; Martín MI
Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
[TBL] [Abstract][Full Text] [Related]
6. Cross-tolerance between mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus.
Garaulet JV; Laorden ML; Milanés MV
J Pharmacol Exp Ther; 1994 Jun; 269(3):993-9. PubMed ID: 8014886
[TBL] [Abstract][Full Text] [Related]
7. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat.
Ignar DM; Kuhn CM
J Pharmacol Exp Ther; 1990 Dec; 255(3):1287-95. PubMed ID: 2175800
[TBL] [Abstract][Full Text] [Related]
8. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
9. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices.
Suarez-Roca H; Maixner W
J Pharmacol Exp Ther; 1993 Feb; 264(2):648-53. PubMed ID: 7679733
[TBL] [Abstract][Full Text] [Related]
10. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
Alcaraz C; Vargas ML; Milanés MV
Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296
[TBL] [Abstract][Full Text] [Related]
11. Opioid modulation of the fetal hypothalamic-pituitary-adrenal axis: the role of receptor subtypes and route of administration.
Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):129-35. PubMed ID: 9103489
[TBL] [Abstract][Full Text] [Related]
12. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
Eisenberg RM
J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
[TBL] [Abstract][Full Text] [Related]
13. The effect of mu and kappa opioid receptor agonists on cAMP level in hippocampus of kainic acid-treated rats.
Dziedzicka-Wasylewska M; Przewłocki R
Pol J Pharmacol; 1995; 47(2):121-6. PubMed ID: 8688884
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues.
Capasso A; Di Giannuario A; Loizzo A; Pieretti S; Sagratella S; Sorrentino L
J Pharmacol Exp Ther; 1996 Feb; 276(2):743-51. PubMed ID: 8632345
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
16. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
J Pharmacol Exp Ther; 1996 May; 277(2):877-84. PubMed ID: 8627570
[TBL] [Abstract][Full Text] [Related]
17. Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
Garaulet JV; Milanés MV; Laorden ML
J Pharmacol Exp Ther; 1995 Feb; 272(2):658-62. PubMed ID: 7853179
[TBL] [Abstract][Full Text] [Related]
18. Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
Iyengar S; Kim HS; Wood PL
Brain Res; 1987 Dec; 435(1-2):220-6. PubMed ID: 2892574
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
20. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
Vonvoigtlander PF; Lahti RA; Ludens JH
J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
